Aratana Therapeutics receives first FDA approval
Galliprant, a pain control medication, first in a new class of drugs.
Aratana Therapeutics has received Food And Drug Administration (FDA) approval of Galliprant (grapiprant tablets), according to a company release. The medication is used for the control of pain and inflammation associated with osteoarthritis in dogs and is expected to be available in fall 2016.
Galliprant is a prostaglandin E2 (PGE2) EP4 receptor antagonist (PRA), a non-cyclooxygenase inhibiting, nonsteroidal anti-inflammatory drug, which blocks PGE2-elicited pain and inflammation.
"As the first approved product in the new piprant class, Galliprant offers veterinarians a needed therapeutic option for the millions of dogs treated each year for osteoarthritis," says Steven St. Peter, MD, president and CEO of Aratana, in the release. "Clinical studies have shown Galliprant offers proven efficacy when compared to placebo and is well-tolerated in dogs."
Podcast CE: A Surgeon’s Perspective on Current Trends for the Management of Osteoarthritis, Part 1
May 17th 2024David L. Dycus, DVM, MS, CCRP, DACVS joins Adam Christman, DVM, MBA, to discuss a proactive approach to the diagnosis of osteoarthritis and the best tools for general practice.
Listen
FDA approves oral drug for broad canine protection against parasites
October 7th 2024Elanco's lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets (Credelio Quattro) provide a single monthly dose for protection against fleas, ticks, heartworms, roundworms, hookworms, and 3 species of tapeworm.
Read More
